Navigation Links
RXi Pharmaceuticals to Ring the NASDAQ Stock Market Closing Bell
Date:8/4/2014

temprop="name">Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI‑109, a self-delivering RNAi compound (sd-rxRNA®), entered into human clinical trials in June 2012 and is currently being evaluated in Phase 2 clinical trials to reduce the formation of dermal scars (fibrosis).  RXI-109 is designed to reduce the expression of connective tissue growth factor (CTGF), a critical regulator of biological pathways involved in fibrosis, including scar formation in the skin.  RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use and have drug-like properties, such as high potency, target specificity, serum stability, reduced immune response activation, and efficient cellular uptake. These hybrid oligonucleotide molecules combine the beneficial properties of conventional RNAi and antisense technologies.  This allows sd‑rxRNAs to achieve efficient cellular uptake and potent, long-lasting intracellular activity. For more information, please visit www.rxipharma.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks and uncertainties:  the risk that we may not be able to successfully develop our candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based products; risks that the development process for our product candidates may be delayed, risks related to the development and commercialization of products by our competitors, the risk related to
'/>"/>

SOURCE RXi Pharmaceuticals Corporation
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars
2. Galmed Pharmaceuticals Reports First Half 2014 Financial Results
3. SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services
4. Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC
5. Vanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
6. ImQuest Pharmaceuticals Receives FDA Approval to Initiate Clinical Trials of a Vaginal Gel for the Prevention of HIV Transmission to Women
7. Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria
8. Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy
9. RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders
10. Collaborations, FDA Approvals, Appointments, Patents, and Stock Movements - Research Report on Aetna, United Therapeutics, Perrigo, Arena Pharmaceuticals, and Keryx Biopharmaceuticals
11. Shimadzu’s New Aggregates Sizer Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... ReliantHeart, Inc., an innovative supplier of ... of precision transit-time flow measurement solutions, are collaborating on ... efficiency of the HeartAssist5® Left Ventricular Assist ... greater mobility and peace of mind. , The ... will draw 1/6th of the power required by earlier ...
(Date:3/26/2015)... Ale Gicqueau, Founder and President of Clinovo, will co-present ... Technology, on “ Conducting Postmarket Registries - Rationale and ... and Exhibition on April 25th through April 28th in ... presentation, Ale Gicqueau and Victor Chen will discuss the ... requirements and resources to conduct the registry, as well ...
(Date:3/25/2015)... is one of the most attractive in the emerging ... a growing economy and increasing government investment in healthcare, ... Russian market is set to grow at twice the ... around 10-15% annually reaching an approximate market value of ... Green Cross provides total healthcare solutions that ...
(Date:3/25/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... of recent discussions with certain shareholders representing approximately 45% ... after dealing with certain matters including the appointment of ... on March 26, 2015 (the "Meeting") it intends to ... will take place when the Meeting reconvenes. The Meeting ...
Breaking Biology Technology:LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 2Clinovo Presents at ACRP 2015 in Salt Lake City, Utah on April 25th-28th 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
... , , , , , , , ... , As a laboratory technician, pipetting ... for a good portion , of the day. Pipetting work ... of the tests being conducted, only short breaks , can ...
... , , , , , , ... by mechanical forces. Use suitable large-bore pipet tips or equipment when , ... , Place ... may be stored at 20C. To minimize possible cross-contamination, , ...
... , , , , , , , ... procedure.(1,2,3), The basic protocol given here works with E. coli cultures grown for ... or DYT, or in 250 , ml Terrific Broth. , ... bacteria from the culture at 10,000 x g for 5 minutes at room , ...
Cached Biology Technology:Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 2Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 3Ergonomics and Liquid Handling, How can BrinkmannTM Help ? 4Mouse Tail Genomic DNA Isolation Protocol(1) 2Basic Plasmid DNA Isolation Protocol 2
(Date:3/23/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), a ... announces its biometric payment technology, the Wocket® smart wallet, will ... 30 th . The new 30 ... markets. Gino Pereira , ... ad campaign following the recent initial shipment of Wocket smart ...
(Date:3/19/2015)... March 19, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market, announces its biometric payment ... clip that aired this week on Washington DC,s ... In a segment "The Next Great Thing", host ... way to pay, and ,a really big breakthrough in mobile ...
(Date:3/16/2015)... March 16, 2015 Between ... will present groundbreaking innovations in biometric identification at ... .      (Photo: http://photos.prnewswire.com/prnh/20150316/735333 ... innovation is well at the forefront: the company,s ... made in Germany . BiometricGate ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 2DERMALOG Presents its Latest Biometric Innovations at the Hannover CeBIT Exhibition, 16 - 20 March 2015 3
... at Le Bonheur Children,s Hospital in Memphis, Tenn., are ... in humans, mutate to avoid the immune response and ... medical director of Molecular Diagnostics and Virology Laboratories at ... and Molecular Biology at The University of Tennessee Health ...
... known for nearly a century that cold-blooded animals, such ... cold environments, but have not known exactly why. , ... have identified a genetic program that promotes longevity of ... in warm-blooded animals, including humans. , "This raises the ...
... of Nanyang Technological University (NTU) has received the prestigious ... his contribution to biomedical sciences. The Fellowship was ... 6pm London time), at Imperial College,s Faculty of Medicine, ... and his outstanding contributions to the development of the ...
Cached Biology News:Leading RSV researcher publishes work at Le Bonheur Children's 2Leading RSV researcher publishes work at Le Bonheur Children's 3Stay cool and live longer? 2NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists 2NTU Provost receives prestigious Imperial College fellowship joining the ranks of top UK scientists 3
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Complement C1q subcomponent subunit C precursor. [Source:Uniprot/SWISSPROT;Acc:P02747] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Mouse monoclonal [CRC64] to Integrin alpha 2b + beta 3 ( Abpromise for all tested applications). Antigen: Human platelets Entrez Gene ID: 23295 Swiss Protein ID: P05106...
Rabbit polyclonal to NCoR2, prediluted ( Abpromise for all tested applications). entrezGeneID: 9612 SwissProtID: Q9Y618...
Biology Products: